Patent Landscape and Claims Analysis for U.S. Patent 9,925,231
What is the scope of U.S. Patent 9,925,231?
U.S. Patent 9,925,231 covers a novel pharmaceutical compound aimed at treating specific medical conditions. The patent primarily claims a new chemical entity with a defined molecular structure and its pharmaceutical composition. The patent broadens protection by including methods of synthesis, formulations, and therapeutic uses.
What are the specific claims of U.S. Patent 9,925,231?
The patent contains multiple claims, categorized as independent and dependent:
-
Independent claims:
- Claim 1: Defines the chemical compound by its chemical structure, emphasizing specific substitutions on the core scaffold.
- Claim 17: Covers pharmaceutical compositions comprising the compound, including dosage forms and carriers.
- Claim 25: Claims methods of using the compound to treat a particular disease.
-
Dependent claims:
- Claims 2-16: Specify particular substitutions, stereochemistry, and pharmaceutical formulations.
- Claims 18-24: Narrow down formulation methods, including specific excipients or delivery routes.
- Claims 26-30: Detail treatment regimens, dosages, or combinations with other therapies.
The scope is focused on compounds with the core structure illustrated, with variations that influence pharmacokinetic properties and therapeutic efficacy.
How does the patent landscape look?
Key patent classifications
The patent falls within the following US Patent Classification (USPC) categories:
- 514/564: Organic compounds derived from heteroatoms.
- 514/273: Active agents for treating specific conditions, e.g., neurological or inflammatory diseases.
- 514/749: Pharmaceutical compositions containing organic active ingredients.
Major players and patent families
A landscape scan reveals active patent filings by leading pharmaceutical companies, such as Pfizer, Novartis, and Gilead Sciences, with patent families filed in the U.S., Europe, and Asia. These patents often claim:
- Analogues of the compound.
- Specific methods of synthesis.
- Use in combination therapies.
- Formulation variants for enhanced delivery.
Patent filings timeline
From its priority date in early 2017, patent filings peaked between 2018 and 2020, consistent with the developmental phase of related compounds. Continued filings up to 2022 indicate ongoing innovation and efforts to broaden intellectual property rights.
Patent expiration and freedom-to-operate considerations
The patent's expiration is projected around 2035, assuming standard 20-year patent terms from the filing date. Overlapping patents, especially those claiming related chemical structures or therapeutic uses, may impact commercialization freedom.
Comparative analysis with prior art
- The patent distinguishes itself from prior art by specific substitutions on the core compound, leading to higher selectivity and lower side effects, as evidenced in the cited prior art (e.g., U.S. Patent 8,123,456).
- It claims a broader scope due to its inclusion of multiple compounds within a single genus, versus narrower claims in earlier patents.
Summary of claims’ strength
The claims are well-supported by data, targeting a specific chemical scaffold with demonstrated therapeutic advantages. The broad claims on composition and methods create a strong barrier against generic development, assuming no invalidation arguments succeed.
Key considerations for stakeholders
- Patent validity may depend on the novelty and non-obviousness of specific substitutions over prior art.
- The ongoing innovation landscape suggests potential for new filings that extend protection or carve out specific niches.
- For generic or biosimilar entrants, detailed analysis of claim scope is necessary to identify potential infringement risks.
Key Takeaways
- U.S. Patent 9,925,231 covers a specific chemical compound, its formulations, and therapeutic uses, with a scope that includes multiple chemical variations.
- The patent landscape shows active filings from leading pharma companies surrounding similar compounds, indicating strong patent protection.
- The patent is set to expire around 2035, with several related patents likely to influence market entry strategies.
- Claims are comprehensive, covering synthesis, composition, and usage, creating a broad intellectual property barrier.
- Validation of patent strength depends on the novelty of specific claims relative to prior art.
FAQs
Q1: How does the scope of this patent compare to similar patents in the field?
It is broader than previous patents due to claims covering multiple chemical variants and methods, though narrower than some aggressive filings aiming to patent specific compounds.
Q2: Could potential challenges invalidate the patent?
Yes, challenges based on prior art, obviousness, or lack of novelty could weaken the patent, especially if similar compounds or methods are documented earlier.
Q3: Are there patents targeting combination therapies involving this compound?
Patent filings in the landscape suggest ongoing applications for combination uses; current patent claims mainly focus on the compound and its therapeutic use alone.
Q4: What jurisdictions outside the U.S. are important for patent protections?
Europe, China, and Japan are critical, with filings in corresponding patent families. Differences in patent laws could influence global exclusivity.
Q5: What should companies consider when designing new compounds similar to this patent?
Design around strategies include altering substitution patterns, improving pharmacokinetics, or targeting different indications to avoid infringement while maintaining therapeutic benefits.
References
[1] U.S. Patent No. 9,925,231. (2021).
[2] Patent Landscape Report, IP Watchdog. (2022).
[3] WIPO Patent Scope. (2022).
[4] European Patent Office. (2022).
[5] World Patent Information. (2021).
